Lenalidomide Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Lenalidomide Market is segmented by Application (Multiple Myeloma, Myelodysplastic Syndrome, and Others), End-User (Hospitals, Cancer Treatment Centers, Research Institutes), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, South America). The report offers the value (in USD million) for the above segments.

Lenalidomide Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Lenalidomide Market Size

Lenalidomide Market Size
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
CAGR 5.00 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration Medium

Major Players

Global Lenalidomide Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Global Lenalidomide Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Lenalidomide Market Analysis

The Global Lenalidomide Market is expected to register a CAGR of 5% during the forecast period.

Due to the COVID-19 outbreak, the market has shown a slight decline because of the postponing of multiple myeloma treatment and its diagnosis. For instance, as per the article published in Blood Cancer Journal in December 2021, titled "Impact of COVID-19 in patients with multiple myeloma based on a global data network", the number of new cases diagnosed in 2020 was less than the cases in 2019 and more than 15% of patients have not been diagnosed. Also, the survival of newly diagnosed patients with multiple myeloma is reduced because of the delay in getting treatment. Hence, the delay in diagnosis and treatment has impacted the market for Lenalidomide medication which is used for the treatment of multiple myeloma. Even though COVID has had an impact on the lenalidomide industry, normalcy has now increased in the market.

The major factors increasing the market's growth are the rising prevalence of multiple myeloma globally, higher awareness of the disease and its treatment with the rise in demand for better treatment options, and improving healthcare facilities. The high prevalence of multiple myeloma and myelodysplastic syndromes has a significant impact on the increasing demand for lenalidomide. As per the article published in the National Library of Medicine in May 2020, titled "Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment," the incidence of multiple myeloma globally is 160,000 and mortality are 106,000. Multiple myeloma is responsible for 10% of all hematological cancers. On the other hand, according to the Myelodysplastic Syndromes Foundation, 87,000 new instances of myelodysplastic syndrome are diagnosed each year in the United States, with 75% of those diagnosed being over the age of 60. A total of about 30% of the patients develop acute myeloid leukemia. Thus, the increase in the prevalence of both diseased patients has resulted in a higher demand for lenalidomide for the treatment of these diseases. However, the risk and side effects of the medication can be a restraining factor in future market growth.

Lenalidomide Industry Overview

The Lenalidomide market is moderately competitive, with several players across the globe. In terms of market share, various major players currently dominate the market. With the rising treatment facilities and high prevalence of diseases, some regional players are expected to be part of the Lenalidomide market over the forecast period. The key players in the market of Lenalidomide are Sandoz, Delphis Pharma, Celgene Corporation, Dr. Reddy's Laboratories, Teva Pharmaceuticals, Cipla, Reliance Life Sciences, and Hetero Healthcare, Synthon, Deva.

Lenalidomide Market Leaders

  1. Sandoz

  2. Dr. Reddy’s Laboratories 

  3. BRISTOL-MYERS SQUIBB COMPANY (Celgene)

  4. Teva Pharmaceuticals 

  5. Cipla

  6. *Disclaimer: Major Players sorted in no particular order
Allscripts Healthcare Solutions Inc., Koninklijke Philips N.V., OTH.IO, International business Machinery Corporation (IBM), and AMD Global Telemedicine Inc.
Need More Details on Market Players and Competiters?
Download PDF

Lenalidomide Market News

In March 2022, Natco Pharma announced the launch of the first generic version of Celgene's top-selling cancer medicine Revlimid (lenalidomide capsules) in the United States market with its marketing partner Arrow International, an affiliate of Israeli pharma maker Teva Pharmaceutical Industries.

In February 2022, Sandoz launched generic lenalidomide across Europe in 19 countries resulting in expanding access to essential oncology medicine.

Lenalidomide Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increase in Prevalence of Myeloma
    • 4.2.2 Rise in Demand for Better Treatment Options
  • 4.3 Market Restraints
    • 4.3.1 Side effects and high cost of medication
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 By Application
    • 5.1.1 Multiple Myeloma
    • 5.1.2 Myelodysplastic syndromes
    • 5.1.3 Others
  • 5.2 By End User
    • 5.2.1 Hospitals
    • 5.2.2 Cancer Treatment Centers
    • 5.2.3 Research Institutes
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.1.4 Rest of North America
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 Saudi Africa
    • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Dr Reddys Laboratories
    • 6.1.2 Celgene
    • 6.1.3 Cipla
    • 6.1.4 Delphis Pharma
    • 6.1.4.1 http://www.delphispharma.com/delphispharma-apis/lenalidomide/
    • 6.1.5 Sandoz
    • 6.1.5.1 https://www.sandoz.com/search-results?query=Lenalidomide
    • 6.1.6 Reliance Life Sciences
    • 6.1.6.1 https://www.rellife.com/web/lifesciences/relidomide
    • 6.1.7 Teva
    • 6.1.8 Hetero Healthcare
    • 6.1.8.1 https://www.heterohealthcare.com/lynide-lenalidomide-drugs-manufacturer
    • 6.1.9 Deva Pharma
    • 6.1.9.1 https://www.deva.com.tr/en/awards
    • 6.1.10 Synthon
    • 6.1.10.1 https://www.synthon.com/generics/product-portfolio
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Lenalidomide Industry Segmentation

As per the scope of this report, lenalidomide sold under the trade name Revlimid is a medication that is taken orally and is used to treat diseases such as multiple myeloma, myelodysplastic syndromes, and smoldering myeloma. Lenalidomide Market is segmented by application (multiple myeloma, myelodysplastic syndrome, and others), end-user (hospitals, cancer treatment centers, research institutes), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Application Multiple Myeloma
Myelodysplastic syndromes
Others
By End User Hospitals
Cancer Treatment Centers
Research Institutes
Geography North America United States
Canada
Mexico
Rest of North America
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa GCC
Saudi Africa
Rest of Middle-East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Lenalidomide Market Research FAQs

What is the current Global Lenalidomide Market size?

The Global Lenalidomide Market is projected to register a CAGR of 5% during the forecast period (2025-2030)

Who are the key players in Global Lenalidomide Market?

Sandoz, Dr. Reddy’s Laboratories, BRISTOL-MYERS SQUIBB COMPANY (Celgene), Teva Pharmaceuticals and Cipla are the major companies operating in the Global Lenalidomide Market.

Which is the fastest growing region in Global Lenalidomide Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Global Lenalidomide Market?

In 2025, the North America accounts for the largest market share in Global Lenalidomide Market.

What years does this Global Lenalidomide Market cover?

The report covers the Global Lenalidomide Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Lenalidomide Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Global Lenalidomide Industry Report

Statistics for the 2025 Global Lenalidomide market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Lenalidomide analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.